CRC-话题@MedSci

#CRC#

70篇内容 | 2130人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1827278, encodeId=4408182e27856, content=<a href='/topic/show?id=52e95194b9' target=_blank style='color:#2F92EE;'>#CRC#</a>, objectTitle=JNCCN:左侧RAS/RAF野生型(WT) 转移性结直肠癌（mCRC）患者治疗策略趋势和预后, objectType=article, longId=299670, objectId=2fd12996e0f7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2fd12996e0f7, replyNumber=0, likeNumber=50, createdTime=2022-09-20, rootId=0, userName=yxch36, userId=4cea26, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2fd12996e0f7, moduleTitle=JNCCN:左侧RAS/RAF野生型(WT) 转移性结直肠癌（mCRC）患者治疗策略趋势和预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2fd12996e0f7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1827271, encodeId=334e182e271a9, content=<a href='/topic/show?id=52e95194b9' target=_blank style='color:#2F92EE;'>#CRC#</a>, objectTitle=Front Oncol：左侧RAS/BRAF野生型转移性结直肠癌(mCRC)患者一线抗表皮生长因子受体(EGFR)为基础治疗后后续维持治疗管理, objectType=article, longId=219570, objectId=1d282195e0e7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1d282195e0e7, replyNumber=0, likeNumber=35, createdTime=2021-12-18, rootId=0, userName=yxch36, userId=4cea26, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1d282195e0e7, moduleTitle=Front Oncol：左侧RAS/BRAF野生型转移性结直肠癌(mCRC)患者一线抗表皮生长因子受体(EGFR)为基础治疗后后续维持治疗管理, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1d282195e0e7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1827269, encodeId=ec88182e269b5, content=<a href='/topic/show?id=52e95194b9' target=_blank style='color:#2F92EE;'>#CRC#</a>, objectTitle=Eur Urol：ccRCC患者中，PARP1预测PD-L1阻断治疗反应的效果如何？, objectType=article, longId=219447, objectId=234a21944e5a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=234a21944e5a, replyNumber=0, likeNumber=53, createdTime=2022-02-03, rootId=0, userName=yxch36, userId=4cea26, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=234a21944e5a, moduleTitle=Eur Urol：ccRCC患者中，PARP1预测PD-L1阻断治疗反应的效果如何？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=234a21944e5a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1827273, encodeId=6322182e2732c, content=<a href='/topic/show?id=52e95194b9' target=_blank style='color:#2F92EE;'>#CRC#</a>, objectTitle=Front Oncol：原发肿瘤大小对结直肠癌（CRC）生存的预测和预后影响, objectType=article, longId=264983, objectId=effd2649830c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=effd2649830c, replyNumber=0, likeNumber=37, createdTime=2022-04-14, rootId=0, userName=yxch36, userId=4cea26, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=effd2649830c, moduleTitle=Front Oncol：原发肿瘤大小对结直肠癌（CRC）生存的预测和预后影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=effd2649830c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1827272, encodeId=881a182e272d4, content=<a href='/topic/show?id=52e95194b9' target=_blank style='color:#2F92EE;'>#CRC#</a>, objectTitle=Front Oncol：PD-1抑制剂camrelizumab（卡瑞利珠单抗）+XELOX化疗联合贝伐珠单抗或regorafenib（瑞戈非尼）作为一线治疗mCRC的有效性和安全性, objectType=article, longId=221101, objectId=e69e221101af, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e69e221101af, replyNumber=0, likeNumber=41, createdTime=2022-01-13, rootId=0, userName=yxch36, userId=4cea26, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e69e221101af, moduleTitle=Front Oncol：PD-1抑制剂camrelizumab（卡瑞利珠单抗）+XELOX化疗联合贝伐珠单抗或regorafenib（瑞戈非尼）作为一线治疗mCRC的有效性和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e69e221101af)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1827266, encodeId=47bf182e26603, content=<a href='/topic/show?id=52e95194b9' target=_blank style='color:#2F92EE;'>#CRC#</a>, objectTitle=Cancers：结直肠癌（CRC）患者辅助化疗后血浆中CEA, CA19-9, IL-6, CRP,和 YKL-40水平预测疾病进展的提前时间和预后作用, objectType=article, longId=215266, objectId=4d022152664b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4d022152664b, replyNumber=0, likeNumber=31, createdTime=2021-11-04, rootId=0, userName=yxch36, userId=4cea26, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4d022152664b, moduleTitle=Cancers：结直肠癌（CRC）患者辅助化疗后血浆中CEA, CA19-9, IL-6, CRP,和 YKL-40水平预测疾病进展的提前时间和预后作用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4d022152664b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1827268, encodeId=4281182e26833, content=<a href='/topic/show?id=52e95194b9' target=_blank style='color:#2F92EE;'>#CRC#</a>, objectTitle=Front Oncol：转移性结直肠癌（mCRC）患者使用标准的一线治疗时，KRAS G12C突变与其他亚型对于治疗的应答以及预后的比较, objectType=article, longId=218078, objectId=d5152180e802, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d5152180e802, replyNumber=0, likeNumber=41, createdTime=2021-10-25, rootId=0, userName=yxch36, userId=4cea26, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d5152180e802, moduleTitle=Front Oncol：转移性结直肠癌（mCRC）患者使用标准的一线治疗时，KRAS G12C突变与其他亚型对于治疗的应答以及预后的比较, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d5152180e802)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1827267, encodeId=6175182e26751, content=<a href='/topic/show?id=52e95194b9' target=_blank style='color:#2F92EE;'>#CRC#</a>, objectTitle=Nat Commun：综合风险评分（CRC）系统：鼻咽癌筛查和风险分层的新型预测指标, objectType=article, longId=216772, objectId=e427216e7201, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e427216e7201, replyNumber=0, likeNumber=36, createdTime=2022-03-18, rootId=0, userName=yxch36, userId=4cea26, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e427216e7201, moduleTitle=Nat Commun：综合风险评分（CRC）系统：鼻咽癌筛查和风险分层的新型预测指标, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e427216e7201)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1827270, encodeId=a811182e270fe, content=<a href='/topic/show?id=52e95194b9' target=_blank style='color:#2F92EE;'>#CRC#</a>, objectTitle=Front Oncol：原发性肿瘤位置(PTL)对于mCRC患者后线使用REG或FTD/TPI治疗的影响, objectType=article, longId=219546, objectId=ba20219546f3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ba20219546f3, replyNumber=0, likeNumber=31, createdTime=2022-07-09, rootId=0, userName=yxch36, userId=4cea26, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ba20219546f3, moduleTitle=Front Oncol：原发性肿瘤位置(PTL)对于mCRC患者后线使用REG或FTD/TPI治疗的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ba20219546f3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1827264, encodeId=4a66182e26424, content=<a href='/topic/show?id=52e95194b9' target=_blank style='color:#2F92EE;'>#CRC#</a>, objectTitle=BRAIN：线粒体UQCRC1突变导致常染色体显性帕金森氏症伴多发性神经病, objectType=article, longId=205166, objectId=bbc8205166d8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bbc8205166d8, replyNumber=0, likeNumber=41, createdTime=2021-06-28, rootId=0, userName=yxch36, userId=4cea26, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bbc8205166d8, moduleTitle=BRAIN：线粒体UQCRC1突变导致常染色体显性帕金森氏症伴多发性神经病, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bbc8205166d8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1827265, encodeId=096a182e26515, content=<a href='/topic/show?id=52e95194b9' target=_blank style='color:#2F92EE;'>#CRC#</a>, objectTitle=ASCO GI 2021：帕博利珠单抗可显著改善MSI-H/dMMR mCRC患者的PFS（KEYNOTE-177研究）, objectType=article, longId=205930, objectId=92a920593034, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=92a920593034, replyNumber=0, likeNumber=28, createdTime=2021-12-15, rootId=0, userName=yxch36, userId=4cea26, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=92a920593034, moduleTitle=ASCO GI 2021：帕博利珠单抗可显著改善MSI-H/dMMR mCRC患者的PFS（KEYNOTE-177研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=92a920593034)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1827263, encodeId=da0c182e263c0, content=<a href='/topic/show?id=52e95194b9' target=_blank style='color:#2F92EE;'>#CRC#</a>, objectTitle=Br J Cancer：错配修复不足的转移性结直肠癌dMMR mCRC患者的生存分析, objectType=article, longId=202147, objectId=30ba20214e5d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=30ba20214e5d, replyNumber=0, likeNumber=44, createdTime=2021-04-18, rootId=0, userName=yxch36, userId=4cea26, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=30ba20214e5d, moduleTitle=Br J Cancer：错配修复不足的转移性结直肠癌dMMR mCRC患者的生存分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=30ba20214e5d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1827260, encodeId=2f18182e260d7, content=<a href='/topic/show?id=52e95194b9' target=_blank style='color:#2F92EE;'>#CRC#</a>, objectTitle=ASCO 2020 | Pembrolizumab或替代化疗在MSI-H / dMMR CRC中一线治疗的地位, objectType=article, longId=195301, objectId=db5919530147, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=db5919530147, replyNumber=0, likeNumber=34, createdTime=2020-11-24, rootId=0, userName=yxch36, userId=4cea26, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=db5919530147, moduleTitle=ASCO 2020 | Pembrolizumab或替代化疗在MSI-H / dMMR CRC中一线治疗的地位, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=db5919530147)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1827261, encodeId=e21f182e2618b, content=<a href='/topic/show?id=52e95194b9' target=_blank style='color:#2F92EE;'>#CRC#</a>, objectTitle=Clinica Chimica Acta：CYC1、SDHA、UQCRC1、UQCRQ和SDHB可能是肾移植排斥反应的重要生物标志物？, objectType=article, longId=196308, objectId=a7e0196308f7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a7e0196308f7, replyNumber=0, likeNumber=35, createdTime=2020-10-04, rootId=0, userName=yxch36, userId=4cea26, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a7e0196308f7, moduleTitle=Clinica Chimica Acta：CYC1、SDHA、UQCRC1、UQCRQ和SDHB可能是肾移植排斥反应的重要生物标志物？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a7e0196308f7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1827259, encodeId=99d9182e25938, content=<a href='/topic/show?id=52e95194b9' target=_blank style='color:#2F92EE;'>#CRC#</a>, objectTitle=Cell Death Dis：敲低lncRNA HOTAIR可通过miR-93/ATG12轴增强CRC的放射敏感性, objectType=article, longId=190236, objectId=0b6a190236b8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0b6a190236b8, replyNumber=0, likeNumber=25, createdTime=2020-06-06, rootId=0, userName=yxch36, userId=4cea26, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0b6a190236b8, moduleTitle=Cell Death Dis：敲低lncRNA HOTAIR可通过miR-93/ATG12轴增强CRC的放射敏感性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0b6a190236b8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1827262, encodeId=0950182e262e1, content=<a href='/topic/show?id=52e95194b9' target=_blank style='color:#2F92EE;'>#CRC#</a>, objectTitle=Cell Death & Disease：UBAC2通过BCRC-3/miRNA-182-5p/p27途径促进膀胱癌增殖, objectType=article, longId=201240, objectId=c86e20124037, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c86e20124037, replyNumber=0, likeNumber=33, createdTime=2020-11-23, rootId=0, userName=yxch36, userId=4cea26, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c86e20124037, moduleTitle=Cell Death & Disease：UBAC2通过BCRC-3/miRNA-182-5p/p27途径促进膀胱癌增殖, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c86e20124037)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1827257, encodeId=912d182e2570c, content=<a href='/topic/show?id=52e95194b9' target=_blank style='color:#2F92EE;'>#CRC#</a>, objectTitle=GUT：ZEB 1促进结肠炎和炎症性CRC, objectType=article, longId=179241, objectId=e5341e92419a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e5341e92419a, replyNumber=0, likeNumber=34, createdTime=2019-12-21, rootId=0, userName=yxch36, userId=4cea26, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e5341e92419a, moduleTitle=GUT：ZEB 1促进结肠炎和炎症性CRC, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e5341e92419a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1827256, encodeId=bd38182e25653, content=<a href='/topic/show?id=52e95194b9' target=_blank style='color:#2F92EE;'>#CRC#</a>, objectTitle=BRAF、EGFR、MEK，三靶向无化疗方案或成为BRAF V600E突变型mCRC新标准治疗, objectType=article, longId=175233, objectId=c5631e5233ba, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c5631e5233ba, replyNumber=0, likeNumber=38, createdTime=2019-07-27, rootId=0, userName=yxch36, userId=4cea26, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c5631e5233ba, moduleTitle=BRAF、EGFR、MEK，三靶向无化疗方案或成为BRAF V600E突变型mCRC新标准治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c5631e5233ba)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1827253, encodeId=ae37182e2535e, content=<a href='/topic/show?id=52e95194b9' target=_blank style='color:#2F92EE;'>#CRC#</a>, objectTitle=GUT：围手术期低血浆VD水平与CRC不良预后相关, objectType=article, longId=165602, objectId=4d4616560271, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4d4616560271, replyNumber=0, likeNumber=54, createdTime=2019-12-24, rootId=0, userName=yxch36, userId=4cea26, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4d4616560271, moduleTitle=GUT：围手术期低血浆VD水平与CRC不良预后相关, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4d4616560271)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1827258, encodeId=f35d182e25885, content=<a href='/topic/show?id=52e95194b9' target=_blank style='color:#2F92EE;'>#CRC#</a>, objectTitle=PLK1抑制剂Onvasertib治疗KRAS突变的mCRC患者：肿瘤消退和临床获益, objectType=article, longId=186925, objectId=3f7618692587, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3f7618692587, replyNumber=0, likeNumber=33, createdTime=2020-03-02, rootId=0, userName=yxch36, userId=4cea26, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3f7618692587, moduleTitle=PLK1抑制剂Onvasertib治疗KRAS突变的mCRC患者：肿瘤消退和临床获益, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3f7618692587)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

CRC

2020-05-29

yxch36 (审核中...)

前往app查看评论内容

#CRC#

JNCCN:左侧RAS/RAF野生型(WT) 转移性结直肠癌（mCRC）患者治疗策略趋势和预后

2022-09-20

yxch36 (审核中...)

前往app查看评论内容

#CRC#

Front Oncol：左侧RAS/BRAF野生型转移性结直肠癌(mCRC)患者一线抗表皮生长因子受体(EGFR)为基础治疗后后续维持治疗管理

2021-12-18

yxch36 (审核中...)

前往app查看评论内容

#CRC#

Eur Urol：ccRCC患者中，PARP1预测PD-L1阻断治疗反应的效果如何？

2022-02-03

yxch36 (审核中...)

前往app查看评论内容

#CRC#

Front Oncol：原发肿瘤大小对结直肠癌（CRC）生存的预测和预后影响

2022-04-14

yxch36 (审核中...)

前往app查看评论内容

#CRC#

Front Oncol：PD-1抑制剂camrelizumab（卡瑞利珠单抗）+XELOX化疗联合贝伐珠单抗或regorafenib（瑞戈非尼）作为一线治疗mCRC的有效性和安全性

2022-01-13

yxch36 (审核中...)

前往app查看评论内容

#CRC#

Cancers：结直肠癌（CRC）患者辅助化疗后血浆中CEA, CA19-9, IL-6, CRP,和 YKL-40水平预测疾病进展的提前时间和预后作用

2021-11-04

yxch36 (审核中...)

前往app查看评论内容

#CRC#

Front Oncol：转移性结直肠癌（mCRC）患者使用标准的一线治疗时，KRAS G12C突变与其他亚型对于治疗的应答以及预后的比较

2021-10-25

yxch36 (审核中...)

前往app查看评论内容

#CRC#

Nat Commun：综合风险评分（CRC）系统：鼻咽癌筛查和风险分层的新型预测指标

2022-03-18

yxch36 (审核中...)

前往app查看评论内容

#CRC#

Front Oncol：原发性肿瘤位置(PTL)对于mCRC患者后线使用REG或FTD/TPI治疗的影响

2022-07-09

yxch36 (审核中...)

前往app查看评论内容

#CRC#

BRAIN：线粒体UQCRC1突变导致常染色体显性帕金森氏症伴多发性神经病

2021-06-28

yxch36 (审核中...)

前往app查看评论内容

#CRC#

ASCO GI 2021：帕博利珠单抗可显著改善MSI-H/dMMR mCRC患者的PFS（KEYNOTE-177研究）

2021-12-15

yxch36 (审核中...)

前往app查看评论内容

#CRC#

Br J Cancer：错配修复不足的转移性结直肠癌dMMR mCRC患者的生存分析

2021-04-18

yxch36 (审核中...)

前往app查看评论内容

#CRC#

ASCO 2020 | Pembrolizumab或替代化疗在MSI-H / dMMR CRC中一线治疗的地位

2020-11-24

yxch36 (审核中...)

前往app查看评论内容

#CRC#

Clinica Chimica Acta：CYC1、SDHA、UQCRC1、UQCRQ和SDHB可能是肾移植排斥反应的重要生物标志物？

2020-10-04

yxch36 (审核中...)

前往app查看评论内容

#CRC#

Cell Death Dis：敲低lncRNA HOTAIR可通过miR-93/ATG12轴增强CRC的放射敏感性

2020-06-06

yxch36 (审核中...)

前往app查看评论内容

#CRC#

Cell Death & Disease：UBAC2通过BCRC-3/miRNA-182-5p/p27途径促进膀胱癌增殖

2020-11-23

yxch36 (审核中...)

前往app查看评论内容

#CRC#

GUT：ZEB 1促进结肠炎和炎症性CRC

2019-12-21

yxch36 (审核中...)

前往app查看评论内容

#CRC#

BRAF、EGFR、MEK，三靶向无化疗方案或成为BRAF V600E突变型mCRC新标准治疗

2019-07-27

yxch36 (审核中...)

前往app查看评论内容

#CRC#

GUT：围手术期低血浆VD水平与CRC不良预后相关

2019-12-24

yxch36 (审核中...)

前往app查看评论内容

#CRC#

PLK1抑制剂Onvasertib治疗KRAS突变的mCRC患者：肿瘤消退和临床获益

2020-03-02

科室
- - 订阅+
  - 更多科室
工具
服务